文献速递临床试验与 GCP基础与转化研究

单剂ChAdOx1 nCoV-19疫苗诱导的T细胞与抗体应答:1/2期临床试验探索性分析

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
PubMed 文献 · Nat Med · 2020-12-17

该研究为1/2期临床试验的探索性分析,纳入18-55岁成人,评估单剂ChAdOx1 nCoV-19疫苗接种后8周内的免疫应答。结果显示疫苗诱导Th1偏向的CD4+ T细胞应答(干扰素-γ和肿瘤坏死因子-α分泌)及以IgG1和IgG3为主的抗体产生,同时诱导CD8+ T细胞应答。这些结果支持该疫苗候选株进入正在进行的2/3期有效性试验。

要点

  • 单剂ChAdOx1 nCoV-19可诱导Th1偏向的CD4+ T细胞应答和IgG1/IgG3抗体产生。
  • 疫苗同时诱导单功能、多功能及细胞毒性表型的CD8+ T细胞。
  • 免疫特征良好,支持该疫苗进入2/3期有效性试验。

核心结论

  • 单剂ChAdOx1 nCoV-19在18-55岁成人中诱导有利的Th1偏向免疫特征,支持进入2/3期试验。

研究设计与样本

  • 1/2期临床试验(NCT04400838)的探索性分析,评估18-55岁成人单剂接种后8周内的免疫应答。

主要发现

  • CD4+ T细胞分泌干扰素-γ和肿瘤坏死因子-α,呈现Th1偏向。
  • 抗体以IgG1和IgG3亚类为主。
  • 诱导单功能、多功能及细胞毒性表型的CD8+ T细胞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed1. Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses2 and might reduce the potential for disease enhancement3. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection4. Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. 5,6). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)7 given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-γ and tumor necrosis factor-α cytokine secretion by CD4+ T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8+ T cells, of monofunctional, polyfunctional and cytotoxic phenotypes, were also induced. Taken together, these results suggest a favorable immune profile induced by ChAdOx1 nCoV-19 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess vaccine efficacy.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020. PMID: 33335323. doi:10.1038/s41591-020-01194-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。